DexCom, Inc.

DexCom, Inc. is an American medical device company that designs, manufactures, and sells continuous glucose monitoring (CGM) systems for people with diabetes, generating $4.66 billion in revenue in fiscal 2025. Its flagship G7 sensor, worn on the body for up to 15 days, transmits real-time glucose readings to a smartphone, replacing the fingerstick-based monitoring that dominated diabetes care for decades. Dexcom's systems are used by roughly 2.5 million people worldwide, and the company employs approximately 11,100 people with headquarters in San Diego, California.

This is a story about whether the dominant franchise in a medically essential category can extend its growth runway beyond the type 1 diabetes market that built it. Dexcom has delivered a remarkable expansion — revenue has roughly doubled since 2021 — but the shares have fallen more than 40% from their 2024 peak as the market questions what the next act looks like. The company's core type 1 and intensive insulin-using type 2 markets are maturing in the United States, and the next leg of growth depends on unlocking coverage for the roughly 12 million Americans with type 2 diabetes who do not use insulin — a population for which CGM is not yet reimbursed by Medicare. The file turns on a single question: whether that coverage arrives before the competitive and pricing pressures that are a feature of large medical-device markets compress Dexcom's economics.

The bull case is straightforward: CGM penetration of the covered U.S. population is only about 30%, the clinical evidence for expanding coverage keeps getting stronger, and Dexcom's product lead — particularly with the newly launched G7 15-day sensor — is widening at exactly the right moment. The bear case is that the type 2 non-insulin coverage unlock is already priced into every conversation but not yet into revenue, that Abbott's FreeStyle Libre remains a formidable competitor with a larger international installed base, and that the gross margin story has more moving parts than a simple volume-leverage narrative implies. Both sides have evidence worth weighing.